Consolidated statement of cash flows

Download (XLSX, 36 KB)
Consolidated statement of cash flows
January 1 to December 31, € in millions Note 2020 2019
Operating activities      
Net income   2,823 3,029
Adjustments to reconcile net income to cash and
cash equivalents provided by operating activities		      
Depreciation and amortization 18, 19, 20, 31 2,715 2,452
Change in deferred taxes 11 43 71
Gain on sale of fixed assets and of investments and divestitures 2 -60 -107
Changes in assets and liabilities, net of amounts
from businesses acquired or disposed of		      
Trade accounts and other receivables 16 -26 -612
Inventories 17 -527 -315
Other current and non-current assets 18 -252 -368
Accounts receivable from / payable to related parties   13 19
Trade accounts payable, provisions and
other short-term and long-term liabilities		 21, 22 1,819 67
Accruals for income taxes   1 27
Net cash provided by operating activities   6,549 4,263
Investing activities      
Purchases of property, plant and equipment
and capitalized development costs		 19 -2,406 -2,459
Proceeds from sales of property, plant and equipment   40 26
Acquisitions and investments
and purchases of intangible assets		 2, 34 -720 -2,484
Proceeds from sale of investments and divestitures 2 75 61
Net cash used in investing activities   -3,011 -4,856
Download (XLSX, 35 KB)
Consolidated statement of cash flows
January 1 to December 31, € in millions Note 2020 2019
Financing activities      
Proceeds from short-term debt 23 282 1,029
Repayments of short-term debt 23 -2,529 -936
Proceeds from long-term debt 23 61 2,016
Repayments of long-term debt 23 -1,438 -1,541
Repayments of lease liabilities 31 -937 -837
Proceeds from the issuance of bonds 24 4,577 3,174
Repayments of liabilities from bonds 24 -937 -1,767
Repayments of convertible bonds 25 -400 -500
Payments for the share buy-back program of Fresenius Medical Care 28 -366 -600
Payments for / proceeds from the accounts receivable
facility of Fresenius Medical Care		 23 -374 381
Proceeds from the exercise of stock options 36 18 49
Dividends paid   -1,060 -952
Change in noncontrolling interests, net 27 -14 –
Net cash used in financing activities   -3,117 -484
Effect of exchange rate changes on cash and cash equivalents   -238 22
Net increase / decrease in cash and cash equivalents   183 -1,055
Cash and cash equivalents at the beginning of the reporting period 15 1,654 2,709
Cash and cash equivalents at the end of the reporting period 15 1,837 1,654
Download (XLSX, 35 KB)
Additional information on payments that are included in net cash provided by operating activities
January 1 to December 31, € in millions Note 2020 2019
Received interest   66 64
Paid interest   -627 -733
Income taxes paid   -765 -773
The following notes are an integral part of the consolidated financial statements.
Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Visit us

Fresenius SE & Co. KGaA

Consolidated statement of financial position

Consolidated statement of changes in equity